v3.26.1
Sale of Future Revenue - Narrative (Details) - USD ($)
$ in Thousands
2 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 65 Months Ended 68 Months Ended
Nov. 03, 2020
Dec. 31, 2020
Jun. 30, 2026
Jun. 30, 2025
Sep. 30, 2020
Jun. 30, 2020
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Mar. 31, 2026
Jun. 30, 2026
Disaggregation of Revenue [Line Items]                      
Payments for financing costs             $ 3,470 $ 0      
Revenues     $ 13,819 $ 10,003     28,265 $ 18,723      
Royalty                      
Disaggregation of Revenue [Line Items]                      
Revenues             976   $ 938    
MAM Pangolin Royalty , LLC | Maximum                      
Disaggregation of Revenue [Line Items]                      
Proceeds from sale of future revenue $ 125,000                    
License agreement with Sunovion Pharmaceuticals, Inc.                      
Disaggregation of Revenue [Line Items]                      
Minimum annual royalty receivable     1,000     $ 1,000 $ 1,000       $ 1,000
License agreement with Sunovion Pharmaceuticals, Inc. | Royalty                      
Disaggregation of Revenue [Line Items]                      
Revenues         $ 8,000 $ 8,000          
Monetization Agreement                      
Disaggregation of Revenue [Line Items]                      
Payments for financing costs     $ 2,909                
Effective annual interest rate (as a percent) 24.90%                    
Monetization Agreement | MAM Pangolin Royalty , LLC                      
Disaggregation of Revenue [Line Items]                      
Proceeds from sale of future revenue $ 40,000 $ 10,000               $ 50,000 $ 50,000
Proceeds from debt, contingent on additional milestones $ 75,000